Assessment of the Relationship between Expressions of CD34, p63 with Different Clinical Types of Oral Epithelial Dysplasia: A Retrospective Immunohistochemical Study

Mustafa Mohammed Abdulhussain, Fawaz D. Alaswad

International Journal of Biomedicine. 2022;12(4):596-600.
DOI: 10.21103/Article12(4)_OA13
Originally published December 5, 2022


Background: Potentially malignant disorders such as leukoplakia and erythroplakia are often associated with dysplastic changes that have an increased risk for malignant transformation. CD34 is considered as an important marker for tissue vascularization, which represents microvessel density. P63 has a role in epithelial proliferation and is frequently altered in dysplasia and associated with tumorigenesis.
The aim of this study was to evaluate the expression of CD34 and p63 in different grades of oral epithelial dysplasia (OED).
Methods and Results: This research included 50 histopathologically confirmed OED. CD34 and P63 expressions were studied by using the immunohistochemical technique. Most OED lesions were observed in patient between 40 and 69 years of age. Buccal mucosa was the most affected site (42%). According to histopathological grades, mild OED was predominant (54%). There was a significant difference among OED grades through the P63 marker.
Conclusion: The P63 marker can be considered a good indicator for malignant transformation by grade scoring scales, and the CD34 marker can be used as a useful diagnostic indicator for OED.

oral epithelial dysplasia • malignancy • CD34 • P63 • immunohistochemistry

1. Thomas V, Devi SR, Jeyaseelan V, Jeyseelan L. Mucosal Disorders with Oral Epithelial Dysplasia risk–Development of a simple screening tool for general health care setting. Oral Oncol 2012;48(8):671-677.
2. Cheung VKY, Hulme K, Schifter M, Palme C, Low TH, Clark J, Gupta R. Oral Epithelial Dysplasia: A Review of Diagnostic Criteria for Anatomic Pathologists. Adv Anat Pathol. 2022 Jul 1;29(4):227-240. doi: 10.1097/PAP.0000000000000343.
3. Mehanna HM, Rattay T, Smith J, McConkey CC. Treatment and follow-up of oral dysplasia - a systematic review and meta-analysis. Head Neck. 2009 Dec;31(12):1600-9. doi: 10.1002/hed.21131.
4. McCullough MJ, Prasad G, Farah CS. Oral mucosal malignancy and potentially malignant lesions: an update on the epidemiology, risk factors, diagnosis and management. Aust Dent J. 2010;55(suppl 1):61-65.
5. Speight PM. Update on oral epithelial dysplasia and progression to cancer. Head Neck Pathol. 2007 Sep;1(1):61-6. doi: 10.1007/s12105-007-0014-5.
6. Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 2007 Nov;36(10):575-80. doi: 10.1111/j.1600-0714.2007.00582.x.
7. Warnakulasuriya S. Clinical features and presentation of oral potentially malignant disorders. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 Jun;125(6):582-590. doi: 10.1016/j.oooo.2018.03.011.
8. Lorini L, Bescós Atín C, Thavaraj S, Müller-Richter U, Alberola Ferranti M, Pamias Romero J, Sáez Barba M, de Pablo García-Cuenca A, Braña García I, Bossi P, Nuciforo P, Simonetti S. Overview of Oral Potentially Malignant Disorders: From Risk Factors to Specific Therapies. Cancers (Basel). 2021 Jul 23;13(15):3696. doi: 10.3390/cancers13153696.
9. Muller S. Oral epithelial dysplasia, atypical verrucous lesions and oral potentially malignant disorders: focus on histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol 2018;125:591–602.
10. Speight PM, Khurram SA, Kujan O. Oral potentially malignant disorders: risk of progression to malignancy. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 Jun;125(6):612-627. doi: 10.1016/j.oooo.2017.12.011.
11. Iocca O, Sollecito TP, Alawi F, et al. Potentially malignant disorders of the oral cavity and oral dysplasia: A systematic review and meta-analysis of ma-lignant transformation rate by subtype. Head Neck. 2020;42:539-555.
12. WHO Classification of Head and Neck Tumours. El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ, Eds. IARC Press: Lyon, France, 2017.
13. Kujan O, Oliver RJ, Khattab A, Roberts SA, Thakker N, Sloan P. Evaluation of a new binary system of grading oral epithelial dysplasia for prediction of malignant transformation. Oral Oncol. 2006 Nov;42(10):987-93. doi: 10.1016/j.oraloncology.2005.12.014.
14. Nankivell P, Williams H, Matthews P, Suortamo S, Snead D, McConkey C, Mehanna H. The binary oral dysplasia grading system: validity testing and suggested improvement. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Jan;115(1):87-94. doi: 10.1016/j.oooo.2012.10.015.
15. Pritzker KPH, Darling MR, Hwang JT, Mock D. Oral Potentially Malignant Disorders (OPMD): What is the clinical utility of dysplasia grade? Expert Rev Mol Diagn. 2021 Mar;21(3):289-298. doi: 10.1080/14737159.2021.1898949.
16. Raffat MA, Hadi NI, Alghamdi O, Al-Aali KA, Al Deeb M, Abduljabbar T, Vohra F. Expression of Salivary S100A7 Levels in Stage I Oral Submucous Fibrosis: A Clinical and Laboratory Study. Asian Pac J Cancer Prev. 2020 Apr 1;21(4):1115-1119. doi: 10.31557/APJCP.2020.21.4.1115.
17. Roskoski R Jr. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol. 2007 Jun;62(3):179-213. doi: 10.1016/j.critrevonc.2007.01.006.
18. Menakuru SR, Brown NJ, Staton CA, Reed MW. Angiogenesis in pre-malignant conditions. Br J Cancer.2008;99(12):1961-1966. doi:10.1038/sj.bjc.6604733
19. Siar CH, V. P. A. Oo, Nagatsuka H, Nakano K, Ng. KH, Kawakami T. Angiogenic squamous dysplasia-like phenomenon in oral epithelial precursor lesions. Eur J Med Res. 2009;14(7): 315-319.
20. Yong M, Yang L, Suyila Q, et al. Expression and clinical implications of P53, P63, and P73 protein in malignant tumor of the parotid gland. Turk J Med Sci. 2014;44(5):875-882. doi:10.3906/sag-1304-136
21. Yoon MK, Ha JH, Lee MS, Chi SW. Structure and apoptotic function of p73. BMB reports. 2015 48(2):81.
22. Mills AA. p63: oncogene or tumor suppressor? Curr Opin Genet Dev. 2006 Feb;16(1):38-44. doi: 10.1016/j.gde.2005.12.001.
23. Takeda T, Sugihara K, Hirayama Y, Hirano M, Tanuma JI, Semba I. Immunohistological evaluation of Ki67, p63, CK19 and p53 expression in oral epithelial dysplasias. J Oral Pathol Med 2006;35(6):369‑375.
24. Barnes L, Eveson JW, Reichart P, Sidransky D. World Health Organization Classification of Tumors. Pathology and Genetics of Head and Neck Tumours. Lyon: IARC Press; 2005.
25. Sundararajan A, Muthusamy R, Gopal Siva K, Harikrishnan P, Kumar SCK, Rathinasamy SK. Correlation of Mast Cell and Angiogenesis in Oral Lichen Planus, Dysplasia (Leukoplakia), and Oral Squamous Cell Carcinoma. Rambam Maimonides Med J 2021;12(2):e0016.
26. Kamal KAER, Mohamed MA, Abd-alwahab AS, Alazazi M. P63 & ki67 antigen expression in relation to the aggressiveness of oral squamous cell carcinoma. Egyptian Dental Journal (2-April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology). 2020;(66)1091-1098.
27. Niu LX, Feng ZE, Wang DC, Zhang JY, Sun ZP, Guo CB. Prognostic factors in mandibular gingival squamous cell carcinoma: A 10-year retrospective study. Int J Oral Maxillofac Surg. 2017;46(2):137–143.
28. Gopinath D, Thannikunnath BV, Neermunda SF. Prevalence of Carcinomatous Foci in Oral Leukoplakia: A Clinicopathologic Study of 546 Indian Samples. J ClinDiagn Res 2016;10:78-83.
29. Bijina BR, Ahmed J, Shenoy N, Ongole R, Shenoy S, Baliga S. Detection of human papilloma virus in potentially malignant and malignant lesions of the oral cavity and a study of associated risk factors. South Asian Journal of Cancer. 2016;5(4):179-181. doi.10.4103/2278-330X.195337
30. Batool S, Fahim A, Qureshi A, Anas S, Qamar N, Kamran S. Significance of Expression of Cyclin D as an Early Indicator in Dysplastic Transformation of Oral Mucosa in Tobacco Users. JPDA. 2019;28(4):171-175.
31. Napier SS, Speight PM. Natural history of potentially malignant oral lesions & conditions: An overview of the literature. J Oral Pathol Med 2008;37(1):1 10.
32. Pujari RV, Vanaki SS, Puranik RS, Desai RS, Motupalli N, Halawar S. Histomorphometric analysis of vascularity in normal buccal mucosa, leukoplakia, and squamous cell carcinoma of buccal mucosa. J Oral Maxillofac Pathol 2013;
33. Mohammad DN, Garib BT. CD34 and Wnt3 expression in potentially malignant oral disorders. J Bagh Coll Dent. 2017;29:59-67.
34. Krause DS, Fackler MJ, Civin CI, May WS. CD34: structure, biology, and clinical utility. Blood. 1996 Jan 1;87(1):1-13.
35. Bavle RM, Paremala K, Sowmya M, Sudhakara M, Reshma V, Hosthor S. Predicting the Malignant Transformation of Oral Submucous Fibrosis Using Quantitative Biomarkers p63 and CD31. J Orofac Sci. 2020;12:52-60. doi. 10.4103/jofs.jofs_6_20.

Download Article
Received September 28, 2022.
Accepted November 2, 2022.
©2022 International Medical Research and Development Corporation.